FDA Letter API

The Tender Corporation dba Adventure Ready Brand

Letter data

Company
The Tender Corporation dba Adventure Ready Brand
Recipient
Mr. Christopher Heye | Chief Executive Officer | The Tender Corporation dba Adventure Ready Brand | 994 Industrial Park Road | Littleton | , | NH | 03561-3956 | United States | cheye@adventurereadybrands.com
Issue date
2023-09-28
Posted date
Not available
FDA office
Division of Pharmaceutical Quality Operations I
Subject
Not available
Product
Drugs
CMS ID
599789
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER The Tender Corporation dba Adventure Ready Brand MARCS-CMS 599789 — September 28, 2023 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: ELECTRONIC DELIVERY/READ RECEIPT Product: Drugs Recipient: Recipient Name Mr. Christopher Heye Recipient Title Chief Executive Officer The Tender Corporation dba Adventure Ready Brand 994 Industrial Park Road Littleton , NH 03561-3956 United States cheye@adventurereadybrands.com Issuing Office: Division of Pharmaceutical Quality Operations I United States Dear Mr. Heye: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter [CMS #599789], dated July 23, 2020. Based on our evaluation, it appears that you have adequately addressed the violations contained in this Warning Letter. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Respectfully, /S/ Lisa Harlan Acting Program Division Director U.S. Food and Drug Administration Office of Pharmaceutical Quality Operations Division I cc: Mr. John Gaulin Chief Operating Officer The Tender Corporation dba Adventure Ready Brand 994 Industrial Park Road Littleton, NH 03561 – 3956 jgaulin@adventurereadybrands.com Content current as of: 09/29/2023 Regulated Product(s) Drugs